Skip to NavigationSkip to content

Pharma Pricing & Market Access Europe 2011

Tuesday, March 22, 2011 - Friday, March 25, 2011
Hilton London Paddington
London, United Kingdom

Event Type: Conference

Pre-Conference Workshop, Tuesday 22 March 2010


Pre-Conference Worshop: The Price of Global Health

The workshop will provide a comprehensive overview of global pricing and market access issues and analytical techniques. Global payer segments and individual systems of the most important countries will be discussed with respect to their P&MA approval requirements

The workshop will include presentations, group discussions and case studies

Your workshop leader:

Ed Schoonveld, Principal and Leader of the Market Access & Pricing Practice of ZS Associates

ZS Associates is a global management consulting firm specializing in sales and marketing consulting, capability building, and outsourcing. ZS Associates has deep expertise across the sales and marketing spectrum, from the strategic to the tactical.

9am Introduction Mr Ed Schoonveld, Principal, ZS Associates

9.10am Global drug pricing challenges

9.40am Payers and P&R controls

10.20am Morning coffee

10.45am Pricing and drug development

11.05am Global payer segments and country systems

12.30pm Lunch

1.30pm P&MA Frameworks

2.30pm Developing a global pricing strategy

3.30pm Afternoon tea

4pm Research methodologies

5pm Closing


Day One, Wednesday 23 March 2010

8am Registration & coffee

8.45am Opening remarks from the chair

9am Policy challenges in market access for pharmaceuticals in Europe

  • Key economic developments in Europe and their impact on pricing policy
  • New pricing or partnering models being considered or introduced
  • How will the drugs industry respond to these challenges?

Dr Andrea Rappagliosi, Vice President Corporate Relations, GlaxoSmithKline


9.25am Maneuvering changes in the U.S. health care environment

  • Impact of health care reform today
  • Comparative effectiveness research
  • Changes in co-pay and co-insurance
  • Role of coupons and co-pay offsets
  • Implications for price optimization

Mr Ed Schoonveld, Principal, ZS Associates

9.55am Keynote address: US healthcare reform and it impact on market access

  • The sky is falling! Or is it? Either way you must now deal with: The Good (what works), The Bad (what doesn’t work) and The Ugly (what we don’t know).
  • Healthcare enterprise participants must now deal with the dilemmas posed by the ugly, and create a discipline around: accountability, but by whom, for what (knowledge, actions, or outcomes), to whom, and when? Why bother? Is it now irrelevant?
  • Or is it, at long last, refocused on: the oft forgotten and forlorn object of this all: our patient and her clinical and economic wellbeing.

Dr Allan Korn, Senior Vice President, Chief Medical Officer, Blue Cross Blue Shield Association

10.20am Pharmaceutical Industry Perspective

Mr James Scott,-, Applied Policy

11.05am Speed Networking & Morning Refreshments


11.45am The Role of NICE in the new healthcare environment

  • Overview of the major policy developments that impact technology appraisals
  • What is the NICE role in the proposed changes to the drugs approval process
  • How is NICE adapting to the new priorities in both industry and in public health?

Meindert Boysen, Associate Director, NICE

12.10pm Emerging views of a future value based pricing system for the UK

  • Determining value – how do you do it?
  • Managing the transition from the current PPRS to value based pricing
  • How can industry and payers work together to ensure that the best treatments make it to the patient?

Dr Paul Catchpole, Value and Access Director, ABPI

12.35pm France: Latest Developments in Pricing and Reimbursement Policy

  • Drug pricing in France – the rules
  • HAS’s policy on access to innovative treatments
  • The role of HTA in the pricing and reimbursement decision making process
  • New developments that reflect the current economic environment

Prof Lise Rochaix, Member of the Board, HAS

1pm Lunch


2pm Canada: The Evolving P&R Environment

  • Overview of Canadian P&R, market access
  • Impact of the 2010 changes to the PMPRB price guidelines
  • HTA overview: CADTH/CDR, new HTA agencies pCODR, INESSS
  • Risk sharing, listing agreements and the evolving provincial reimbursement schemes
  • Implications of new generics policies on brand pricing and reimbursement
  • Outlook for P&R, market access in Canada

Mr Neil Palmer, Vice President, Pricing & Reimbursement, PDCI Market Access

2.25pm Cancer Drug Reimbursement in Canada: Focus on Ontario

  • Overview of the Ontario Cancer Care plan
  • Update on and trends in cancer drug utilisation
  • Case study of recent listing decisions

Mr Scott Gavura, Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario

2.50pm Valuing New Medicines

  • Impact of the new funding environment.
  • Potential for new models of care
  • The new pressures US/Europe Asia
  • Which diseases/specialties will register most impact?
  • Is a new partnership possible--industry/patients/funders?

Prof Nick Bosanquet, Head of Health Policy, Imperial College

3.15pm Afternoon refreshments


3.45pm Germany: Latest Developments in Pricing and Reimbursement Policy

  • Role of G-BA in drug regulation in Germany
  • Upcoming changes: New law for drug regulation in Germany
  • Obligatory dossier on benefit and costs with market launch
  • Rapid and early assessment of all new drugs
  • The role of IQWiG in the decision making process
  • Consultations and meetings with manufacturers
  • Impact on patients, payers and industry

Dr Stefan Lange, Deputy Director, IQWiG, Germany (subject to final confirmation)

Dr Thomas Muller, Head of Pharmaceuticals, GBA

Dr Rainer Walenta, Director, Global Pricing & Reimbursement, Abbott Products GmbH

4.45pm Italy: Latest Developments in Pricing and Reimbursement policy

  • Access to medicines in Italy under the NHS
  • Criteria for pricing and reimbursement
  • Governance of pharmaceutical expenditure
  • Experiences with risk sharing and conditional reimbursement

Dr Pietro Folino Gallo, Head of Osmed Unit, AIFA

5.10pm Panel discussion

5.40pm Closing remarks

5.45pm The evening drinks reception is an opportunity to relax and network over drinks with conference attendees.

6.45pm End of day one


Day Two Thursday 24 March 2011

8.30am Registration & coffee

8.45am Opening remarks from the chair

9am The role of the pharmaceutical industry in increasing access to medicine

  • Access to Medicine Index, its development and impact
  • How the ATM Foundation defines the role of the pharmaceutical industry and what pharma’s actually can change (or maintain) in their policy and actions to increase access to medicine

Wim Leereveld, Founder & Chair, Access to Medicines Index

9.25am The Dutch reimbursement system in transition: an Echternach procession

  • Healthcare insurance in the Netherlands
  • The reimbursement and financing system
  • The relationship with industry pharmacists and the ministry
  • The appraisal for permanent listing
  • Future trends

Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ

9.50am Norway: Latest changes in reimbursement and pricing policy legislation

  • The distribution chain for pharmaceuticals in Norway
  • Price regulation for patented drugs
  • The role of generic medicines
  • Update on the stepped pricing model
  • Reimbursement schemes and copayments

Ms Helga Festøy, Head of Section, Norwegian Mediines Agency

10.25am Morning refreshments


10.50am South America

  • Latin American Health System Characteristics. A brief description.
  • Regulation of Market Access and Pricing/Reimbursement in selected countries:
    - Argentina
    - Brazil
    - Colombia
    - Mexico
    - Highlights of others

Prof Federico Augustovski, Director of Health Economic Evaluations and Technology Assessment, Institute for Clinical Effectiveness and Health Policy

11.15am Latest Developments in Pricing & Reimbursement Policy in Russia

  • The new Federal Law on circulation of medicines and introduction of pricing regulation – first results
  • Expected changes in the Russian health care financing and reimbursement systems

Maria Avxentyeva, Deputy Director, Research Institute of Clinico-economic Expertise and Pharmacoeconomics, Russian State Medical University

11.40am China

  • Introduction of new drug pricing rules
  • Review of 2009 National Reimbursement Drug List/2010 Provincial Reimbursement Drug List
  • HTA development and roles in decision making process
  • Opportunities/Challenges of market access in China

Ziyan Wang, Senior PRA Manager, Eli Lilly Asia

12.15pm Panel Discussion

12.45pm Lunch

1.40pm Greece

  • Structure of the Greece healthcare system
  • Review of the major changes to pricing and reimbursement in the last 12 months
  • How sustainable are current measure
  • What does the future hold for the Greek pharmaceutical industry

Pascal Apostolides, General Manager, Abbott Laboratories Hellas SA

2.15pm Turkey: Pricing and reimbursement system

  • Overview of Turkish Healthcare and Market Access environment
  • Turkish Pricing system – Past & Future
  • Turkish Reimbursement system – A general outline
  • Future challenges in Turkey for Market Access

Toros Sahin, Pricing and Reimbursement Coordinator, Sanofi-Aventis

2.45pm Panel Discussion: Value Based Pricing – What does this mean?

Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd


3.30pm Defining strategic and company capability for market access

  • The true scope of market access & timelines for market access planning in R&D
  • Understanding payer needs
  • Pricing innovation – some food for thought
  • Impact of risk sharing agreements & future recommendations
  • Understanding the capability requirements for market access

Colin Wight, Chief Executive, GalbraithWight

4pm Patient Access Schemes and Flexible Pricing - a UK perspective

  • Setting a Cost-Effective Price Level
  • Patient Access Schemes and Flexible Pricing
  • Value Based Pricing
  • Planning for success

Martin Brown, Head of Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited

4.30pm Closing remarks

4.45pm End of Conference and afternoon refreshments


Post-conference workshop, Friday 25 March 2011


Post conference workshop: The changing dynamic of market access in Europe

This one day workshop is designed to provide participants with an understanding of the changing landscape for pricing and market access in Europe. The workshop leader will describe recent and prospective changes in the reimbursement legislation, processes and organizations within each country, including market access requirements at national, regional and local level as appropriate.

The workshop will address the implications of these changing requirements for the pharmaceutical and/or medical device manufacturer bringing a new product to market. The primary focus will be on the five major markets in Europe, France, Germany, Italy, Spain and the UK; but examples may include additional markets in Europe and beyond.

Workshop Facilitator: Jim Furniss, Director of Global Market Access Strategies, Bridgehead International Limited

8.30am Registration and Coffee

9am Introductions

Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd

9.10am Overview of healthcare systems in Europe

9.40am Overview of pricing and reimbursement controls in Europe

10.30am Morning refreshments

10.50am The new market access landscape in Germany

11.40am Regionalisation in Spain and Italy

12.15pm Lunch

1.30pm Healthcare reform in England

  • The new structure
  • Value based pricing
  • The implications for pharmaceutical companies

3.30pm Afternoon refreshments

3.50pm Innovative payment schemes and risk sharing

4.30pm Review, discussion and conclusions

5pm End of workshop


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches